BICYCLE THERAPEUTICS PLC — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Legault Pierre | — | Sale | 162 | $31.07 | $5,033 | — | Apr 5, 2021 |
| Keen Nicholas | Chief Scientific Officer | Sale | 10,000 | $30.00 | $300,000 | 28,321 | Mar 31, 2021 |
| Legault Pierre | — | Sale | 10,000 | $30.00 | $300,000 | — | Mar 31, 2021 |
| Legault Pierre | — | Option Exercise | 7,784 | $8.85 | $68,888 | 7,784 | Mar 17, 2021 |
| Legault Pierre | — | Sale | 2,216 | $29.00 | $64,264 | — | Mar 12, 2021 |
| Keen Nicholas | Chief Scientific Officer | Sale | 217 | $28.00 | $6,076 | 38,321 | Mar 12, 2021 |
| Lee Kevin | Chief Executive Officer | Sale | 100 | $31.00 | $3,100 | 258,800 | Feb 5, 2021 |
| Lee Kevin | Chief Executive Officer | Sale | 351 | $33.00 | $11,583 | 258,900 | Jan 20, 2021 |
| Kalowski Lee | President and CFO | Option Exercise | 15,000 | $1.59 | $23,850 | 15,000 | Jan 19, 2021 |
| Lee Kevin | Chief Executive Officer | Sale | 5,000 | $25.00 | $125,000 | 270,085 | Jan 15, 2021 |
| Kalowski Lee | President and CFO | Option Exercise | 10,000 | $1.60 | $16,000 | 10,000 | Jan 14, 2021 |
| Kalowski Lee | President and CFO | Sale | 7,500 | $22.50 | $168,750 | — | Dec 1, 2020 |
| Kalowski Lee | President and CFO | Sale | 530 | $20.00 | $10,600 | — | Nov 27, 2020 |
| Kalowski Lee | President and CFO | Sale | 213 | $20.38 | $4,341 | — | Nov 23, 2020 |
| GLAXOSMITHKLINE PLC | — | Sale | 1,597 | $19.27 | $30,774 | 1,913,678 | Jul 15, 2020 |
| Winter Gregory Paul | — | Option Exercise | 71,450 | — | — | 163,927 | Apr 14, 2020 |
| AQUILA INVESTMENTS IV | — | C | 1,454,411 | — | — | 1,454,411 | May 28, 2019 |
| Cambridge Innovation Capital (Jersey) Ltd | — | Purchase | 314,286 | $14.00 | $4,400,004 | 1,751,437 | May 28, 2019 |
| NG CAROLYN | — | C | 206,767 | — | — | 1,427,151 | May 28, 2019 |
| Vertex Global Healthcare Fund I Pte Ltd. | — | C | 206,767 | — | — | 1,621,168 | May 28, 2019 |
| Novartis Bioventures Ltd | — | C | 636,366 | — | — | 1,601,011 | May 28, 2019 |
| Winter Gregory Paul | — | C | 42,870 | — | — | 92,477 | May 28, 2019 |
| NG CAROLYN | — | Purchase | 571,429 | $14.00 | $8,000,006 | 571,429 | May 28, 2019 |
| SV Life Sciences Fund V (GP), LP | — | Purchase | 377,732 | $14.00 | $5,288,248 | 1,875,637 | May 28, 2019 |
| Anstey Michael | — | C | 1,081,823 | — | — | 1,081,823 | May 28, 2019 |
| BINGHAM KATE | — | C | 13,169 | — | — | 31,654 | May 28, 2019 |
| HARLAND DEBORAH | — | C | 893,195 | — | — | 893,195 | May 28, 2019 |
| GLAXOSMITHKLINE PLC | — | C | 636,366 | — | — | 1,529,561 | May 28, 2019 |